Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Liabilities and Shareholders Equity (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $216.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 1.39% year-over-year to $216.3 million, compared with a TTM value of $810.3 million through Dec 2025, down 5.03%, and an annual FY2025 reading of $216.3 million, up 1.39% over the prior year.
  • Liabilities and Shareholders Equity was $216.3 million for Q4 2025 at Puma Biotechnology, up from $202.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $260.0 million in Q2 2021 and bottomed at $193.7 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $214.1 million, with a median of $209.2 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity rose 14.69% in 2021, then dropped 25.52% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $226.6 million in 2021, then decreased by 2.0% to $222.1 million in 2022, then grew by 3.81% to $230.5 million in 2023, then decreased by 7.46% to $213.3 million in 2024, then rose by 1.39% to $216.3 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for PBYI at $216.3 million in Q4 2025, $202.9 million in Q3 2025, and $194.9 million in Q2 2025.